Full-Time
Director Commercial Analytics and Enablement
Immunome
201-500 employees
Antibody-based therapeutic discovery and development
Compensation Overview
$206.1k - $247.5k/yr
Bothell, WA, USA
In Person
Travel required as needed, up to approximately 20%.
Bachelor's
 Business & Strategy (2) |
|---|
| , |
Get referred to Immunome
See people who can refer or advise you
- A bachelor's degree is required; an advanced degree in Business, Analytics, Economics, Operations, Engineering, or a related field is preferred.
- At least 10 years of experience in biotech or pharmaceutical commercial operations, sales force effectiveness, analytics, field operations, incentive compensation, and/or enablement functions, or equivalent experience.
- Demonstrated experience leading targeting, segmentation, and call planning processes, including refresh cycles and governance in a compliant environment.
- Demonstrated experience defining incentive compensation philosophy and strategy and leading end-to-end plan design, quota and goal setting, administration, payout governance, and remediation or dispute resolution in partnership with Finance, HR, and Legal or Compliance.
- Proven ability to define and operationalize a commercial analytics and reporting strategy and deliver dashboards, KPI tracking, and standardized reporting for performance management and leadership governance routines.
- Strong technical fluency with commercial analytics toolsets such as Excel, Power BI, Tableau, and SQL, and CRM environments such as Salesforce and Veeva.
- Experience managing external vendors and consultants, including defining scope, managing deliverables, and driving outcomes with external partners.
- Ability to travel as needed, up to approximately 20%, and work effectively across time zones with cross-functional teams and external partners.
- Strong analytical problem-solving skills and the ability to translate complex inputs into action-oriented insights and governance-ready outputs.
- Deep understanding of field execution levers, including targeting, call planning, incentive compensation design and administration, operating rhythms, metrics, reporting, and manager coaching.
- Strong understanding of incentive compensation controls and operating mechanics, including crediting, quota and goal logic, payout calculations, documentation, auditability, exception handling, and remediation or true-ups.
- Strong communication and stakeholder management skills, with the ability to align cross-functional teams and drive decisions through data and structured recommendations.
- Ability to design and deliver effective enablement and training to ensure field adoption of analytics, dashboards, and performance routines.
- Strong program and project management skills, including prioritization, change management, and continuous improvement.
- High integrity and a demonstrated commitment to compliant behaviors, transparency, and patient-first execution.
- Own the commercial analytics, reporting, and enablement strategy, multi-quarter roadmap, and operating model across Commercial.
- Establish guiding principles and working norms for alignment, transparency, compliance, operational discipline, and patient-first execution.
- Define the commercial analytics and reporting strategy, including target audiences, decision use cases, cadence, and timing.
- Establish a push-versus-pull reporting model with ownership, refresh expectations, and version control.
- Set visualization and information-design standards, including KPI definitions, drilldowns, thresholds, flags, annotations, and mobile-friendly layouts.
- Translate business priorities into scalable analytics deliverables, operating cadences, and standardized outputs, and measure adoption and iterate based on usage and stakeholder feedback.
- Partner with Commercial leadership on field force structure and provide analytic inputs for sizing, coverage, and deployment decisions.
- Develop and maintain analytical assumptions, scenarios, and decision-support materials for coverage models, workload, capacity, and related tradeoffs.
- Lead territory alignments and rollout and change-management plans with Commercial Operations.
- Lead targeting, segmentation, call planning, and alignment refresh cycles with governance, version control, documentation, and field communication.
- Establish targeting and call-planning business rules and refresh cadence and ensure reliable, field-usable outputs aligned with strategy and compliance expectations.
- Partner with Sales Leadership, Marketing, and Operations to translate field execution expectations into call plans, coaching routines, and performance management.
- Define and evolve the incentive compensation philosophy and strategy for Commercial field roles.
- Partner with Commercial Leadership, Finance, and HR to design incentive compensation plans, including measures, weights, pay mix, thresholds, targets, maximums, payout curves, accelerators, caps, guarantees or SPIFFs, territory, quota, and goal-setting approaches.
- Lead end-to-end incentive compensation administration planning, including eligibility rules, crediting and attribution logic, data inputs, system configuration requirements, calendars, and field communications.
- Design and implement strategic rewards and recognition initiatives.
- Establish and maintain incentive compensation governance controls, including approval workflows, change control, documentation, audit trails, segregation of duties, and exception policy.
- Own incentive compensation payout and close or true-up processes, including payout previews, leadership approvals, and coordination with Finance, HR, Payroll, and external vendors.
- Manage incentive compensation inquiries, dispute resolution, remediation, retroactive adjustments, overpayment recovery or clawbacks, and root-cause prevention.
- Perform ongoing incentive compensation performance analytics and recommend plan optimizations.
- Deliver data visualization and standardized reporting for commercial performance management and insight generation.
- Define KPI frameworks, metric definitions, and standardized reporting views for leadership and field operating rhythms.
- Establish a metrics dictionary and data-quality monitoring for trusted and consistently interpreted dashboards.
- Support evaluation, selection, and optimization of analytics and enablement tools.
- Design and deliver field analytics training and enablement for analytics, dashboards, and performance routines.
- Create role-based training materials, job aids, and standard operating procedures for interpreting insights, translating them into actions, and operating within governance expectations.
- Partner with Enablement or Training and Field Leadership to embed analytics into onboarding, reinforcement, and manager coaching routines.
- Develop and maintain the field operating model and standard operating procedures for targeting governance, performance routines, and analytic workflows.
- Establish standardized processes for analytics requests, prioritization, delivery, and communication.
- Partner with Sales, Marketing, Finance, HR, Legal or Compliance, Commercial Operations, Distribution, and other stakeholders to align analytics outputs and governance routines.
- Maintain documentation, standard operating procedures, and governance controls supporting auditability, appropriate use, and consistent execution.
- Familiarity with incentive compensation and commission platforms such as Xactly, Varicent, Anaplan, SAP Callidus, CaptivateIQ, and Spiff.
- An advanced degree in Business, Analytics, Economics, Operations, Engineering, or a related field.
Immunome identifies antibodies and their targets by studying the immune systems of patients who recover from diseases, to develop first-in-class therapeutics. Its platform analyzes immune responses to discover novel antibodies and their targets, which are then advanced through research and development in partnership with healthcare and medical research clients. The company’s products work by using antibodies discovered from patients’ immune systems to target diseases, potentially enabling new treatments across oncology and other areas. Immunome differentiates itself through a proprietary discovery platform that extracts clinically relevant antibodies from real patient immune responses, enabling collaborations and licensing deals rather than solely pursuing standalone drug sales. The goal is to bring new antibody therapies to patients by forming partnerships, licensing innovations, and eventually delivering approved therapies.
Company Size
201-500
Company Stage
IPO
Headquarters
Bothell, Washington
Founded
2008
Get referred to Immunome
See people who can refer or advise you
Simplify's Take
What believers are saying
- FDA set varegacestat's PDUFA date for April 28, 2027 after strong Phase 3 data.
- Cash and marketable securities totaled $520.0 million on June 30, 2026, funding into 2028.
- IM-1617's first patient dosing on June 11, 2026 expands multiple shots on goal.
What critics are saying
- IM-1617 faces AbbVie's ABBV-400 and Daiichi's crowded TOP1 ADC category by 2027.
- Immunome burned $120.3 million cash in first-half 2026, despite $520.0 million remaining.
- A varegacestat rejection would leave Immunome dependent on early-stage programs and recurring dilution.
What makes Immunome unique
- Varegacestat reached FDA acceptance in July 2026, anchoring Immunome's first near-term asset.
- IM-1617 targets an undisclosed RTK plus immune exclusion, a rare dual-mechanism ADC.
- IM-1021 and IM-3050 broaden the platform across ADC and radioligand modalities.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Dental Insurance
Vision Insurance
401(k) Retirement Plan
401(k) Company Match
Unlimited Paid Time Off
Hybrid Work Options
Flexible Work Hours
Remote Work Options
Paid Vacation
Paid Holidays
Wellness Program
Mental Health Support
Conference Attendance Budget
Professional Development Budget
Stock Options
Company Equity
Phone/Internet Stipend
Home Office Stipend
Growth & Insights and Company News
6 month growth
↑ 21%1 year growth
↑ 21%2 year growth
↑ 9%Immunome reported Q2 2026 financial results, revealing a net loss of $73.1 million. The biotechnology company held $520.0 million in cash, cash equivalents and marketable securities as of 30 June, expected to fund operations into 2028. The FDA accepted Immunome's application for varegacestat, a desmoid tumour treatment, setting an approval decision date of 28 April 2027. Phase 3 trial data showed an 84% reduction in disease progression risk versus placebo. Research and development expenses totalled $59.9 million for the quarter, whilst general and administrative costs reached $18.3 million. Immunome is advancing three additional clinical-stage programmes, with first patients dosed in trials for IM-1617 and IM-3050. The company plans to submit investigational new drug applications for IM-1340 and IM-1335 by late 2026.
Immunome debuts first-in-class ADC targeting mystery immune-excluding receptor tyrosine kinase. June 12, 2026 Bothell, Washington-based Immunome, Inc. (Nasdaq: IMNM) has dosed the first patient in a Phase I first-in-human study of IM-1617, an antibody-drug conjugate directed at an undisclosed receptor tyrosine kinase (RTK) and armed with HC74, the company's proprietary topoisomerase I inhibitor payload. The trial's significance lies partly in its target biology: the RTK in question is described as promoting tumor cell survival while simultaneously mediating immune cell exclusion - a dual role that, if confirmed clinically, could position IM-1617 as relevant in immunologically cold tumors where checkpoint inhibitors have largely failed. The open-label, multicenter dose escalation and expansion study will enroll patients with advanced solid tumors, including colorectal cancer, non-small cell lung cancer, and breast cancer. Primary objectives cover safety, tolerability, and pharmacokinetics, with preliminary anti-tumor activity as an exploratory endpoint. Immunome has not disclosed enrollment targets or an anticipated completion date. Two additional ADC candidates - IM-1340 and IM-1335 - are expected to reach IND submission by mid- and late 2026, respectively, signaling broader platform ambitions beyond this single asset. The rationale for IM-1617 rests on a well-documented but therapeutically underexploited observation: certain receptor tyrosine kinases do not merely sustain tumor cell proliferation but actively remodel the tumor microenvironment to prevent T-cell infiltration. The TAM family RTKs - TYRO3, AXL, and MERTK - are the best-characterized examples, functioning as innate immune checkpoints that suppress dendritic cell and macrophage activity while driving tumor cell survival through PI3K/AKT and RAS/MAPK signaling. AXL in particular has been directly implicated in T-cell exclusion in breast cancer models, where high AXL expression correlated with complete absence of immune infiltration even following radiotherapy. This biology is directly relevant to the three indications Immunome has identified. Approximately 85% of colorectal cancers are microsatellite-stable and immunologically cold, explaining why PD-1/PD-L1 inhibitors have shown no benefit in this population. A comparable subset of non-small cell lung cancers and triple-negative breast cancers similarly fail to respond to immunotherapy, not because of absent antigenicity but because immune cells are physically excluded from the tumor parenchyma. An ADC targeting the RTK responsible for that exclusion could, in principle, simultaneously kill antigen-expressing tumor cells and relieve the suppressive barrier - potentially rendering surviving tumor tissue more susceptible to endogenous or therapeutically induced immune responses. Competitive positioning. The TOP1 inhibitor ADC space is crowded at the payload level but less so at the target level, where differentiation ultimately resides. Daiichi Sankyo and AstraZeneca's DXd platform dominates across HER2, HER3, and TROP2, with multiple Phase II and Phase III assets in NSCLC and breast cancer. AbbVie is advancing ABBV-400, a c-MET-targeted ADC with a proprietary TOP1 inhibitor payload, in NSCLC and colorectal cancer - indications that directly overlap with IM-1617's target population. Because IM-1617's RTK target remains undisclosed, precise competitive mapping is not possible, but the functional description - an RTK driving both survival signaling and immune exclusion - most closely resembles AXL or MERTK biology, neither of which currently has a clinical-stage ADC program of note. Immunome's broader pipeline context is relevant here. Varegacestat, the company's gamma secretase inhibitor for desmoid tumors, has an NDA filed with the US FDA following Phase III data showing 84% reduction in progression risk and a 56% objective response rate - substantially outperforming the current standard. That near-term commercial asset provides a degree of financial and strategic runway for the ADC platform to mature. IM-1021, the ROR1 ADC sharing the HC74 payload with IM-1617, will generate the first human pharmacokinetic and safety data for HC74, which will inform dose selection and linker optimization for subsequent programs including IM-1617. This article was generated with AI assistance and reviewed and edited by the AllSci editorial team Explore more at AllSci News: https://allsci.com/news/
Immunome, a biotechnology company developing targeted cancer therapies, reported first quarter 2026 financial results. The company had cash and cash equivalents of $582.7 million as of 31 March, expected to fund operations into 2028. The company submitted a New Drug Application to the US FDA in April 2026 for varegacestat, a treatment for adults with desmoid tumours. Immunome plans to submit a Marketing Authorisation Application to the European Medicines Agency by year-end 2026. Research and development expenses for the quarter were $46.4 million, whilst general and administrative expenses totalled $13.0 million. Immunome reported a net loss of $53.8 million for the quarter. The company is advancing multiple programmes, including Phase 1 trials for IM-1021 and IM-3050, and recently received IND clearance for IM-1617.
Immunome's Chief Scientific Officer Jack Higgins sold 9,438 shares on 2 April for $204,238, reducing his direct holdings by 30% to 22,000 shares. The sale was executed under a pre-arranged Rule 10b5-1 trading plan established in December 2025 for financial diversification. The transaction comes as the clinical-stage biotechnology company approaches a significant milestone: its lead candidate varegacestat met the primary endpoint in a Phase 3 trial in December 2025, with an FDA submission planned for the second quarter of 2026. Immunome expects three additional investigational new drug applications and early data from IM-1021 across 2026. The company's stock has risen 250% over the past year, bringing its market capitalisation to $2.40 billion.
Immunome has reported a reduced full-year net loss of $212.39 million for 2025 and filed a $156.03 million common stock shelf registration linked to an employee stock option plan offering. The biotechnology company also updated investors on progress in its oncology pipeline. The company plans to file a New Drug Application for varegacestat following positive Phase 3 data, with multiple solid tumour investigational new drug applications also in development. However, Immunome remains deeply unprofitable despite the narrower losses. The shelf registration raises concerns about potential equity dilution and ownership overhang. Fair value estimates from analysts vary widely, ranging from approximately $29 to over $215 per share, reflecting significant uncertainty around the company's prospects as it advances its high-risk oncology platform.